LEN vs OMCL · rev $34.19B vs P/E 90, rev $1.11B
LEN (LEN) versus Omnicell Inc (OMCL) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Omnicell Inc (OMCL) is a health information services company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported OMCL revenue for 2024-12-31 was $1.11B. Net income was $12.5M. Revenue was down 3.0% from 2023-12-31 to 2024-12-31. OMCL currently screens at market cap $1.80B and trailing P/E 89.9.
LEN currently screens at market cap $0. OMCL currently screens at market cap $1.80B and trailing P/E 89.9.
Not investment advice. Open the LEN and OMCL stock pages for the full models.
Not investment advice.